Close Menu

People in the News

Jan 05, 2021

SomaLogic: Jason Cleveland, Angela Bakker Lee, Tracy Hervey, David McGovern

SomaLogic this week announced several new executive appointments.

Jason Cleveland will be the company's new chief technology officer. He joined SomaLogic in 2015 as a consultant and became a principal research fellow in 2018. Prior to SomaLogic, he was cofounder, chairman, and CEO of Asylum Research, a manufacturer of atomic force microscopes (AFM). He began his career at Digital Instruments, an early AFM maker. Cleveland has a PHD in physics from the Universiy of California, Santa Barbara and is a fellow of the American Physical Society.

SomaLogic has also appointed Angela Bakker Lee as its executive VP for healthcare markets, Tracy Hervey as executive VP for life science markets, and David McGovern as senior VP of marketing.

Prior to SomaLogic, Bakker Lee most recently served as chief strategy officer at Quid, an AI text analytics platform provider. Bakker Lee also previously led IBM's Global Business Services Healthcare for North America. Prior to IBM, Bakker Lee spent 15 years with ZS Associates, a management consulting firm specializing in commercial strategy and sales and marketing operations. Before ZS Associates, she worked at Molecular Applications Group.

Hervey most recently served as chief commercial officer at Amplity Health. Prior to Amplity Health, she served as VP of global accounts at Icon. Before Icon, Hervey held sales leadership roles at data science firm Iqvia and PPD, a global contract research organization.

McGovern previously served as strategic payer marketing lead at Pfizer. Prior to Pfizer, McGovern served as VP of marketing and business development at Change Healthcare. Before Change Healthcare, he held various leadership roles in global commercial development, marketing, and market access at Johnson & Johnson, Merck, and Otsuka. McGovern has also served as VP of marketing at Nupathe, which was later sold to Teva Pharmaceuticals.

Jan 04, 2021

Color: Claire Vo, Emily Reuter, Ashley Chandler

Color has added three individuals to its upper management in connection with a $167 million Series D financing announced this week. Claire Vo will be Color's new chief product officer, having previously held the same title at Optimizely. Emily Reuter is Color's new vice president of strategy and operations, joining the company from Uber, where she was head of investor relations. Ashley Chandler has been named Color's vice president of marketing, and joins the company from Stripe, where she led several marketing functions through a period of rapid growth.

Dec 30, 2020

4basebio: Heikki Lanckriet, David Roth

Heikki Lanckriet and David Roth have resigned from the management board of German company 4basebio (formerly Expedeon). Going forward, they will focus on managing the operational business of the company's UK spinoff, 4basebio SE, which plans to start trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January.

Dec 23, 2020

Diaceutics: Deborah Davis

Diaceutics, a data analytics and services provider for precision medicine, has appointed Deborah Davis as non-executive chair effective Jan. 4, 2021. Davis spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay; and technology companies Symantec and Verizon. She currently holds a number of non-executive director and board committee positions including with International Personal Finance, IDEX Biometrics, the Institute of Directors UK, and Which? Ltd.

Dec 22, 2020

Omniome: Kelly Perez

Omniome, a DNA sequencing technology developer, has promoted Kelly Perez to the position of chief operating officer. Perez has been senior vice president of finance and operations at the company since 2017. Prior to Omniome, she was vice president of corporate development and administration at Sequenom, and vice president of finance at Luxtera.

Dec 22, 2020

Biological Dynamics: Kevin Han

Biological Dynamics, a company developing cancer early detection products, has named Kevin Han as chief financial officer. Previously, Han held positions in investor relations, corporate communications, and corporate sustainability strategies at Bio-Rad Laboratories. Prior to that, he was a portfolio manager for Lombard Odier Asset Management. Han started his career at Morgan Stanley and, later, Goldman Sachs, where he covered the medical technology and diagnostics sectors.

Dec 22, 2020

Danaher: Jose-Carlos Gutierrez-Ramos

Danaher has named Jose-Carlos Gutierrez-Ramos as its chief scientific officer and senior VP. He will be an executive officer of the company tasked with defining Danaher's science and technology strategy. He joins Danaher from Abbvie, where he served as head of global drug discovery. Gutierrez-Ramos also previously served as president and CEO of Repertoire Immune Medicines and Synlogic, and prior to that held R&D positions at Pfizer, GlaxoSmithKline, Avidia, and Millennium Pharmaceuticals. He also was a professor at Harvard Medical School in the Department of Genetics and a professor for the Spanish Scientific Research Council.

Dec 21, 2020

Arrayjet: Joe Keegan, Alan Faichney

Joe Keegan has been appointed non-executive chairman of Arrayjet, an Edinburgh, UK-based provider of liquid handling and bioprinting products for life sciences. Keegan serves as chair of a number of other companies including Carterra, Halo Labs, and Fluidic Analytics. He is also a board member of Bio-Techne, Interpace Biosciences, and Nuclera Nucleics. Keegan holds a BA in chemistry from Boston University and a PhD in physical chemistry from Stanford University.

Keegan will replace Alan Faichney, who is stepping down after seven years in the role.

Dec 16, 2020

Fluidigm: Ana Stankovic

Fluidigm has appointed Ana Stankovic to its board of directors. Stankovic is currently managing partner at Koliada Consulting, a firm focused on biotech, medical devices, and in vitro diagnostics. Previously, she was senior vice president for worldwide regional medical affairs and global health at Becton Dickinson. She served in senior roles at BD for more than a decade, leading medical affairs and clincal operations for various BD units. Prior to this, Stankovic was an associate clinical professor in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine. She also served for two years as a guest lecturer in the Department of Pathology at Harvard Medical School, and is a former chief resident in the Department of Pathology at the University of Alabama at Birmingham.

Dec 14, 2020

Guardant Health: Michael Bell

Guardant Health has named Michael Bell as CFO effective Jan. 4, 2021. He replaces Derek Bertocci who is retiring. Bell has more than 25 years of international finance and accounting experience and has worked in clinical diagnostics, pharma, and public accounting. He was most recently CFO of CareDx and was formerly CFO for Metabiota, Singulex, and Novartis Diagnostics.

Dec 14, 2020

Danaher: Jennifer Honeycutt

Danaher announced it has appointed Jennifer Honeycutt as executive VP, responsible for Beckman Coulter Life Sciences, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and Sciex. Previously, Honeycutt was a VP and group executive overseeing Pall, IDT, and the Danaher Life Sciences platform in China, as well as the president of Pall. From 2013 to 2016, she was president of Beckman Coulter Life Sciences. She joined Danaher in 1999 and served in general management roles at Hach Ultra Analytics, Anderson Instrument Company, and Linx Printing Technologies.

Dec 10, 2020

Molecular Assemblies: Phil Paik

Phil Paik has been appointed as VP of platform development at enzymatic DNA synthesis firm Molecular Assemblies. He joins the San Diego-based company from Illumina, where he was associate director of engineering. Prior to that, he was a founding member of Advanced Liquid Logic. He also served as senior microfluidics design engineer at ICx Technologies.

Dec 10, 2020

New York Genome Center: Scientific Advisory Board Members

The New York Genome Center has created a 10-member scientific advisory board. Chair of the board is Barbara Wold, professor of molecular biology and director of the Merkin Institute for Translational Research at the California Institute of Technology.

The other members are:

  • Goncalo Abecasis, VP of analytical genomics and data sciences at Regeneron Pharmaceuticals and professor of biostatistics at the University of Michigan
  • Bissan Al-Lazikani, professor of cancer and drug discovery data science and head of data science at the Institute of Cancer Research in London
  • Ewan Birney, director, joint head of research, and senior scientist at EMBL's European Bioinformatics Institute in Cambridge, UK
  • Nancy Cox, director of the Vanderbilt Genetics Institute, director of the division of genetic medicine, and professor of genetics at Vanderbilt School of Medicine
  • Joseph Gleeson, professor of neurosciences and pediatrics at Rady Children's Institute of Genomic Medicine
  • Joakim Lundeberg, professor of gene technology at the KTH Royal Institute of Technology and director of the national genomics infrastructure platform, Science for Life Laboratory, in Stockholm
  • Jonathan Pritchard, professor of population studies in the departments of genetics and biology at Stanford University
  • Jay Shendure, director of the Brotman Baty Institute and professor of genome sciences at the University of Washington and a Howard Hughes investigator
  • Matthew State, professor and chair of the department of psychiatry and behavioral sciences and executive director of the UCSF Child, Teen, and Family Center, as well as president of the Langley Porter Psychiatric Hospital and Clinics, Weill Institute for Neurosciences, at the University of California San Francisco
Dec 10, 2020

CareDx: Michael Bell, Marcel Konrad

CareDx said that CFO Michael Bell has notified the company of his intent to resign, effective Dec. 31. The firm has appointed Marcel Konrad to serve as interim CFO, effective upon Bell's resignation. 

Konrad has served as vice president and corporate controller at CareDx since August 2018. Prior to joining the company, he served in various capacities at Santen between November 2013 and July 2018, including as CFO for Santen USA, and as global head of R&D finance and CFO for Santen Ventures. Prior to that, Konrad worked for Novartis for nine years in both Switzerland and the US in various roles. 

Dec 10, 2020

Biofidelity: Robert Osborne

Biofidelity has appointed Robert Osborne as its chief operating officer. Osborne previously served as senior VP of technology and assay development at Inivata. Prior to Inivata, Osborne served as principal staff scientist at the Wellcome Trust Sanger Institute, director of technology development at its spinout company, 14M Genomics, and director of research at Population Genetics Technologies.

Dec 09, 2020

Micronoma: Martin Blaser, Leena Das-Young, Ravid Straussman, Rob Knight,

Micronoma has formed its scientific advisory board, which includes Martin Blaser, Leena Das-Young, Ravid Straussman, and Rob Knight.

Blaser currently serves as the Henry Rutgers chair of the Human Microbiome, professor of medicine and pathology, and as director of the Center for Advanced Biotechnology and Medicine at Rutgers University.

Das-Young previously served as the head of late-phase oncology development at Pfizer. She has also served in senior leadership roles at Guardant Health.

Straussman is a principal investigator at the Weizmann Institute in Rehovot, Israel.

Knight is a cofounder of Micronoma and currently serves as the founding director of the Center for Microbiome Innovation and professor of pediatrics and computer science & engineering at the University of California, San Diego.

Dec 09, 2020

Ares Genetics: Arne Materna, Andreas Posch, Achim Plum

OpGen subsidiary Ares Genetics has announced founding CEO and Managing Director Andreas Posch and Managing Director Achim Plum will step down from their positions, effective Dec. 31. They will both stay on as special advisors throughout 2021 to ensure a smooth transition.

Arne Materna has been appointed managing director and CEO, effective Jan. 1. Materna previously served as vice president, products at CosmosID and has held leadership roles at Qiagen, CLCbio, and Pacific Biosciences. He has particular expertise in microbiology and next-generation sequencing and has experience developing bioinformatics platforms and products.

Dec 07, 2020

Gen InCode: Paul Foulger

Gen InCode, an Oxford, UK-based company specializing in AI-powered genetic risk assessment for cardiovascular disease, has appointed Paul Foulger as CFO. Foulger previously served as group finance director at EKF Diagnostics, and is currently a non-executive director of Arcis Biotechnology and Autoclenz. He has also previously served as finance director at NovaBiotics, Elsevier Science, Venn Life Sciences, and PredictImmune, among other companies.

Dec 04, 2020

Waters: Sherry Buck, Michael Silveira

Waters announced this week that CFO Sherry Buck will step down as CFO at the end of this month. She has taken a position at a privately held firm, Waters said. Michael Silveira, currently VP and corporate controller at Waters, will assume the role of interim CFO. Waters said it is working with an executive search firm to identify a permanent CFO.

Dec 04, 2020

Rhinostics: Cheri Walker

Cheri Walker has been appointed president and CE of Rhinostics, a Cambridge, Massachusetts-based sample collection device firm. Walker has served in management roles at Invitrogen, Qiagen, Charles River Laboratories, Kailos Genetics, and most recently was senior VP of corporate development at Abcam. 

Dec 03, 2020

InterVenn Biosciences: John Leite

John Leite has become chief business officer at InterVenn Biosciences, based in South San Francisco. Previously, he was VP of oncology, market development, and product marketing for Illumina's oncology business. Prior to that, he was VP of commercial strategy and market access for Genoptix, and earlier in his career, he was a scientist at Invitrogen. Leite holds a PhD in biochemistry from the University of Pittburgh School of Medicine.

Dec 03, 2020

4basebio: Hansjörg Plaggemars, Alexander Link

Hansjörg Plaggemars has been appointed to the executive management board of 4basebio in Germany. He also resigned from the firm's supervisory board, effective Nov. 29, and is replaced by Alexander Link, who was elected as a substitute member to the board on Nov. 3.

Dec 02, 2020

Datavant: Mark Karch

Datavant has hired Mark Karch as chief commercial officer. He comes the startup health data integrator and analytics firm from IQvia, where he led software-as-a-service technology sales following that company's acquistion of Appature, where Karch had been executive VP of commercialization. Karch also was EVP of the former pharmaceutical business at Allscripts Healthcare Solutions, the health IT vendor with roots in drug repackaging.

Dec 01, 2020

Congenica: Muthu Meyyappan

Congenica has hired Muthu Meyyappan as chief commercial officer. Meyyappan will lead the UK-based company's global sales and marketing efforts from Congenica's US headquarters in Boston. He comes to Congenica from Variantyx, where he also served as CCO. Previous jobs include VP for advanced genomics commercial operations at Qiagen and chief business officer for Biobase, a company Qiagen acquired in 2014.

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Pages

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.